Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493575 | 0.81 | KMT2A (0.45) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4493574 | 0.78 | MAPT (0.46) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4501636 | 0.74 | MKNK1 (0.46) | KMT2AMEN1MAPK1LMNAL3MBTL1 | |
| SCHEMBL5686482 | 0.73 | ALDH1A1 (0.48) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30509874 | 0.72 | NNMT (0.45) | ALDH1A1POLBKDM4E | |
| SCHEMBL31582882 | 0.72 | NNMT (0.45) | ALDH1A1POLBKDM4E | |
| SCHEMBL427541 | 0.72 | ATM (0.68) | SMN1; SMN2ALDH1A1POLBKDM4EATM | |
| Ammonia Solution, Strong SCHEMBL10556485 | 0.71 | ATM (0.66) | SMN1; SMN2ALDH1A1POLBKDM4EATM | |
| SCHEMBL30422501 | 0.70 | MKNK1 (0.42) | NPC1KMT2AMEN1ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL8621698 | 0.69 | ATM (0.63) | SMN1; SMN2ALDH1A1POLBKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | NPC1 4710/4885RAB9A 4716/4885KMT2A 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.